Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
AstraZeneca announces positive top-line data from two phase III SYMBICORT studies
AstraZeneca today announced positive top-line results from two international, multicenter studies in adult and pediatric patients with chronic obstructive pulmonary disease (COPD) and asthma, respectively, that showed SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol was well tolerated and achieved the primary endpoints in both studies.
AstraZeneca diabetes diet and lifestyle support program, Fit2Me™, extends to include cardiovascular health
AstraZeneca today announced the extension of its free diet and lifestyle support program, Fit2Me™, to include resources for patients who face challenges associated with cardiovascular risk and disease. In the United States today, approximately 27 million people are living with type 2 diabetes. Adults with diabetes are two to four times more likely to have heart disease or a stroke than adults without diabetes. Type 2 diabetes and cardiovascular disease are complex and chronic conditions and maintaining a healthy lifestyle can help people manage their diabetes and reduce cardiovascular risk factors.
TAGRISSO® (osimertinib) met primary endpoint in phase III 2nd-line lung cancer trial
AstraZeneca today announced that the AURA3 Phase III trial met its primary endpoint, demonstrating superior progression-free survival (PFS) compared to standard platinum-based doublet chemotherapy. The AURA3 randomized trial assessed the efficacy and safety of TAGRISSO® (osimertinib) as a second-line treatment in more than 400 patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed following first-line EGFR tyrosine kinase inhibitor (TKI) therapy. TAGRISSO also demonstrated a safety profile consistent with previous trials.
AstraZeneca provides update on FluMist Quadrivalent vaccine in the US for the 2016-17 influenza season
AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal), a Live Attenuated Influenza Vaccine (LAIV), in the US for the 2016-2017 influenza season. The updated guidance states the vaccine should not be used in any setting, based on CDC vaccine effectiveness data from the last three influenza seasons, which indicated FluMist Quadrivalent did not demonstrate statistically significant effectiveness in children 2-17 years of age.
AstraZeneca introduces AZhelps, an innovative savings and support program to help patients with their medicines
AstraZeneca today announced it has expanded its patient support offerings to include AZhelps, a comprehensive and unique program that helps patients manage information across all their medications, access savings offers for their AstraZeneca medicines, and easily access healthcare support through their mobile devices and on social media channels.
Latest AZ&You Blog Articles
Making Medicine Personal in Cancer Treatments
Cancer is one of mankind’s greatest scientific and health challenges. Today, nearly 14.5 million Americans have cancer and the total annual cost of their treatment is estimated at $125 billion. With astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system.
Interactive Teaching Model Engages Students in STEM
Not long ago, Emma Waldman was a fifth grader just outside of Boston, Massachusetts, disengaged from her classes in science and math. “[They] were always hard to conceptualize, I never really saw them as practical or important,” says Emma. She is certainly not alone; 83% of students in the United States are not proficient or not interested in science, technology, engineering and math (STEM) fields by eighth grade.
Making Medicine Personal in Cardiovascular and Metabolic Health
Cardiovascular and metabolic diseases are complex and require life-long attention. Patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. Our goal at AstraZeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. We do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner.
Mobile Savings and Support App Offers Patients New Ways to Manage Health
When managing your health, convenience is key. We all want tools that enable us to lead healthier lives while saving us time and money. That’s why AstraZeneca is introducing an industry leading digital support program called AZhelps, built to help you better manage your AstraZeneca medications and your health.
Patient influencers bring medical meetings to life online
We recently took a look at how social media has transformed medical meetings, enabling attendees to engage and connect in real time, but also allowing anyone with internet access to join the conversation from wherever they are. As we approach the American Diabetes Association’s 76th Scientific Sessions taking place June 10-14, those at the meeting will take to social media to share their #2016ADA experience with the world, from new research presented to exploring New Orleans and everything in between.
Harnessing the Immune System to Potentially Revolutionize Cancer Treatment for Patients
This year alone, nearly 1.7 million new cancer cases are expected to be diagnosed in the United States. A patient newly diagnosed with cancer, after absorbing the unwanted news from his or her physician, will want to know, “What treatments will I need? Where do I begin?”
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.